**ARTICLE**

BNT162b2-elicited neutralization of Delta plus, Lambda, Mu, B.1.1.519, and Theta SARS-CoV-2 variants

Jianying Liu 1,2,9, Yang Liu 1,9, Hongjie Xia 3, Jing Zou 3, Scott C. Weaver 1,2,4,5,6, Kena A. Swanson 7, Hui Cai 7, Mark Cutler 7, David Cooper 7, Alexander Muik 6, Kathrin U. Jansen 7, Ugur Sahin 8, Xuping Xie 4,10, Philip R. Dormitzer 8,70, and Pei-Yong Shi 2,3,4,5,6,10

BNT162b2-elicited human sera neutralize the currently dominant Delta SARS-CoV-2 variant. Here, we report the ability of 20 human sera, drawn 2 or 4 weeks after two doses of BNT162b2, to neutralize USA-WA1/2020 SARS-CoV-2 bearing variant spikes from Delta plus (Delta-AY.1, Delta-AY.2), Delta-Δ144 (Delta with the Y144 deletion of the Alpha variant), Lambda, B.1.1.519, Theta, and Mu lineage viruses. Geometric mean plaque reduction neutralization titers against Delta-AY.1, Delta-AY.2, and Mu viruses are slightly lower than against USA-WA1/2020, but all sera neutralize the variant viruses to titers of ≥80, and neutralization titers against the Delta-Δ144, Lambda, B.1.1.519 and Theta variants not significantly reduced relative to those against USA-WA1/2020. The susceptibility of Delta plus, Lambda, B.1.1.519, Theta, Mu, and other variants to neutralization by the sera indicates that antigenic change has not led to virus escape from vaccine-elicited neutralizing antibodies and supports ongoing mass immunization with BNT162b2 to control the variants and to minimize the emergence of new variants.

**INTRODUCTION**

As of October 25, 2021, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused over 243 million infections and more than 4.9 million deaths due to coronavirus disease 2019 (COVID-19; https://coronavirus.jhu.edu/). Since its emergence in late 2019, SARS-CoV-2 has accumulated mutations, leading to variants with higher transmission, more efficient replication, and potentially immune evasion 1-5. Many of these mutations have occurred in the viral spike glycoprotein, which is responsible for binding to the host receptor, angiotensin-converting enzyme 2, during virus entry. Based on the effects of mutations on viral transmission, disease severity, and clinical diagnosis, the World Health Organization (WHO) has categorized SARS-CoV-2 strains into “variants of concern (VOC),” “variants of interest (VOI),” and “variants under monitoring (VUM)” (https://www.who.int/en/activities/tracking-SARS-CoV-2-variants/). As of the submission of this study in September 2021, VOC include Alpha (B.1.1.7), Beta (B.1.351), Gamma (P.1), and Delta (B.1.617.2); VOI include Lambda (C.37) and Mu (B.1.621). As the pandemic continues, it is critical to monitor closely the new variants for their transmission, pathogenesis, and potential escape from vaccines and therapeutics.

BNT162b2 is an mRNA vaccine expressing the full-length prefusion spike glycoprotein of SARS-CoV-2, stabilized in the prefusion conformation 6. BNT162b2 has recently been approved for vaccination of individuals 16 years of age and older and has been authorized under emergency use provisions for immunization of those 5–15 years old by the US Food and Drug Administration. Although BNT162b2 mRNA encodes the original spike protein from the Wuhan isolate 7, the sera of those immunized with BNT162b2 can neutralize all tested variants, including the currently circulating Delta variant 2,8-13. However, some variants are less efficiently neutralized than others, with the Beta and Kappa variants showing the greatest decrease to date 8-10. The explosive recent spread of the Delta variant to 119 countries and its association with breakthrough infections in vaccinated people prompted us to examine the closely related Delta plus variants, such as (i) Delta-AY.1 (first detected in India and spread to 52 countries, including the USA); (ii) Delta-AY.2 (first detected in the USA and spread to 11 countries); and (iii) Delta-Δ144 (first detected in Vietnam and spread to 17 countries) (https://www.gisaid.org/hcov19-variants/). In addition to the Delta variants, the Lambda variant (C.37; first detected in Peru) has spread to 46 countries with high prevalence in South America; the Theta variant (P.3; first identified in the Philippines) was considered as a VOI from February to July of 2021; the Mu variant (B.1.621; first documented in Colombia) has been found in 61 countries; the B.1.1.519 variant has emerged and become dominant in Mexico during the first months of 2021 (https://www.gisaid.org/hcov19-variants/). Consequently, the WHO has designated the Delta sublineages, Delta-AY.1 and Delta-AY.2, as VOC, Lambda and Mu as VOI, and B.1.1.519 as VUM. Here, we report BNT162b2 vaccine-elicited neutralization against these new variants.

**RESULTS**

**BNT162b2-elicited neutralization of SARS-CoV-2 variants**

We aimed to study the impact of antigenic variation in the SARS-CoV-2 spike glycoprotein on neutralization by antibodies elicited by the wild type (WT) spike glycoprotein encoded by BNT162b2 RNA. Therefore, we used a reverse genetic system to generate a panel of SARS-CoV-2 with a USA-WA1/2020 genetic background (a viral strain isolated in January 2020 and defined as WT) and spike
glycoproteins from the newly emerged variants (Supplementary Fig. 1a). Seven chimeric SARS-CoV-2s were prepared: (i) Delta-AY.1-spike with T19R, T95I, G142D, E156G, F157/R158 deletion (∆144), A243-L244 deletion (Δ144), D253N, L452Q, F490S, D614G, and T859N (GISAID accession ID: EPI_ISL_876555); (ii) Delta-AY.2-spike with T19R, V70F, G142D, E156G, ∆157/158, A222V, K417N, L452R, T478K, D614G, P681R, and D950N (GISAID accession ID: EPI_ISL_1138413); (iii) Lambda-spike with G75V, T76I, R246-G252 deletion (∆144-146), A243-L244 deletion (∆243-244), Y265C, E484K, E156G, F157/R158 deletion (∆144-spike (a Delta variant that has acquired a Y144-deletion from the Alpha variant) with T19R, G142D, ∆144, E156G, ∆157/158, A222V, L452R, T478K, D614G, P681R, and D950N (GISAID accession ID: EPI_ISL_2373110); (iv) Lambda-spike with G75V, T76I, R246-G252 deletion (∆246-252), D253N, L452Q, F490S, D614G, and T859N (GISAID accession ID: EPI_ISL_1138413); (v) B.1.1.519-spike with T478K, D614G, P681R, and T732A (GISAID accession ID: EPI_ISL_1525395); (vi) Lambda-spike with T19R, T95I, insertion 143T, Y144S, Y145N, R346K, E484K, N501Y, D614G, P681H, and D950N (GISAID accession ID: EPI_ISL_343007). The WT and all seven chimeric viruses were rescued from infectious cDNA clones and titered by plaque assay on Vero E6 cells. Theta-spike and Mu-spike viruses developed smaller plaques than other chimeric variant viruses (Supplementary Fig. 1b). All chimeric viruses had infectious titers of greater than $10^7$ plaque-forming units (PFU)/ml. The ratio of viral RNA to PFU was quantified for each virus; no significant differences in viral RNA-to-PFU ratios were detected between the WT and chimeric variant viruses (Supplementary Fig. 1c), indicating similar specific infectivities. Sequencing of viral stocks confirmed that there were no undesired mutations in the spike gene.

We compared the neutralization susceptibility of the chimeric variant SARS-CoV-2s to a panel of 20 sera collected from BNT162b2-immunized human participants in the pivotal clinical trial. As reported previously, the serum specimens were prepared 2 or 4 weeks after two immunizations with $30 \mu g$ of BNT162b2, spaced three weeks apart. Each serum was tested simultaneously for its 50% plaque reduction neutralizing titers (PRNT$_{50}$) against the WT and chimeric variant viruses (Supplementary Table 1). All the sera neutralized the WT and all the mutant viruses with titers of 1:80 or higher (Fig. 1). The geometric mean neutralizing titers against the WT, Delta-AY.1-spike, Delta-AY.2-spike, Delta-Δ144-spike, Lambda-spike, B.1.1.519-spike, Theta-spike, and Mu-spike viruses were 520, 355, 394, 453, 597, 640, 469, and 288, respectively (Fig. 1). The neutralizing titers against the Mu variant were the lowest of the titers against any of the 7 viruses tested in this study. However, the reduction in titer against the Mu variant is not as great as the reduction in titer observed previously against the Beta variant, and BNT162b2 protects against disease caused by Beta variant strains. The neutralization of Delta plus variants Delta-AY.1 and Delta-AY.2, is only modestly reduced relative to neutralization of WT virus. We previously reported a similar neutralization result for another Delta plus strain, Delta-AY.3 (B.1.617.2.v2). Neutralization of the Delta-Δ144, Lambda B.1.1.519, and Theta variants is not reduced relative to neutralization of WT virus. Overall, BNT162b2 immune sera efficiently neutralized all tested viruses.

**DISCUSSION**

We have taken a systematic approach to measuring BNT162b2-elicted neutralization of newly emerged variants. We use a reverse genetic system to generate chimeric SARS-CoV-2’s bearing spikes from distinct variants through site-directed mutagenesis or DNA synthesis. This approach has two major advantages: (i) it allows us to examine new variants as soon as their sequences become available, and (ii) it measures the impact of variant spikes on neutralizing activity without being affected by mutations outside the spike gene. Non-spike mutations are not directly relevant to the selection of vaccine spike sequences. We test all chimeric variants for neutralization by the same panel of 20 sera from BNT162b2-vaccinated trial participants, enabling us to make well controlled comparisons longitudinally to inform vaccine decision making.

Our previous and current results suggest that BNT162b2-vaccinated sera neutralize the Delta and Delta plus variants more efficiently than they neutralize the Beta variant. Real-world effectiveness of two doses of BNT162b2 against Beta variant-associated severe or fatal disease in Qatar and vaccine efficacy against Beta variant-associated COVID-19 in South Africa were both reported to have point estimates of 100%. These results
suggest that the observed breakthrough disease associated with the Delta variant is not due to antigenic change. The waning of neutralizing titers after two doses of vaccine appears to be a greater contributor to breakthrough COVID-19\textsuperscript{15,17}. A third dose of BNT162b2 addresses the waning by eliciting neutralizing titers against wild type virus higher than those after the second dose as well as broader neutralization against the Delta and Beta variants\textsuperscript{17}.

Recent studies using primary human airway cultures and a human lung epithelial cell line suggest that the Delta variant has improved replication fitness through mutagenesis P681R-enhanced protease cleavage of the full-length spike to S1 and S2 subunits, as one mechanism leading to increased viral infection\textsuperscript{13,19}. Viral RNA loads in the oropharynx from Delta variant-infected patients were over 1000-fold higher than those from the original Wuhan virus-infected individuals\textsuperscript{20,21}. Collectively, the results suggest that improved viral fitness due to more efficient furin cleavage, rather than immune escape, may account for breakthrough infections of the Delta variant in vaccinated people. More efficient furin cleavage of the influenza fusion protein, hemagglutinin, increases viral pathogenicity to an even greater extent.

One limitation of this study is the potential for mutations to alter neutralization by affecting spike function rather than antigenicity (e.g., mutation P681R that improves viral replication through enhanced spike processing), despite the variant viruses exhibiting specific infectivities similar to that of the original USA-WA1/2020 virus on Vero E6 cells. Another limitation is that the study focuses only on the effect of spike glycoprotein mutations on neutralization in cell culture. Mutations outside the spike gene may also alter viral replication and/or host immune response.

The susceptibility of Delta, Delta plus, Lambda, Mu, and other variants to BNT162b2-elicited neutralization indicates that antigenic change does not yet appear to be the major mechanism of increased Delta variant pathogenicity or spread. This finding suggests that changing the strain of the spike glycoprotein encoded by the vaccine may not be the most effective response to the emergence and spread of the Delta variant. Nevertheless, Pfizer and BioNTech are preparing for the possibility that a strain of the vaccine may also alter viral replication and/or host immune response.

The NPJ Vaccines paper by J. Liu et al. describes recent studies using primary human airway cultures and a human lung epithelial cell line to assess the Delta variant's fitness through mutation P681R-enhanced protease cleavage of the full-length spike to S1 and S2 subunits, as one mechanism leading to increased viral infection. Viral RNA loads in the oropharynx from Delta variant-infected patients were over 1000-fold higher than those from the original Wuhan virus-infected individuals. Collectively, the results suggest that improved viral fitness due to more efficient furin cleavage, rather than immune escape, may account for breakthrough infections of the Delta variant in vaccinated people. More efficient furin cleavage of the influenza fusion protein, hemagglutinin, increases viral pathogenicity to an even greater extent.

One limitation of this study is the potential for mutations to alter neutralization by affecting spike function rather than antigenicity (e.g., mutation P681R that improves viral replication through enhanced spike processing), despite the variant viruses exhibiting specific infectivities similar to that of the original USA-WA1/2020 virus on Vero E6 cells. Another limitation is that the study focuses only on the effect of spike glycoprotein mutations on neutralization in cell culture. Mutations outside the spike gene may also alter viral replication and/or host immune response.

The susceptibility of Delta, Delta plus, Lambda, Mu, and other variants to BNT162b2-elicited neutralization indicates that antigenic change does not yet appear to be the major mechanism of increased Delta variant pathogenicity or spread. This finding suggests that changing the strain of the spike glycoprotein encoded by the vaccine may not be the most effective response to the emergence and spread of the Delta variant. Nevertheless, Pfizer and BioNTech are preparing for the possibility that a strain of the vaccine may also alter viral replication and/or host immune response.

### Methods

**Cells**

Vero E6 cells, an African green monkey kidney epithelial cell line (ATCC, Manassas, VA, USA), were cultured in Dulbecco's modified Eagle's medium (DMEM; Gibco/Thermo Fisher, Waltham, MA, USA) with 10% fetal bovine serum (FBS; HyClone Laboratories, South Logan, UT) plus 1% ampicillin/streptomycin (Gibco). The authenticity of Vero E6 cells was verified through STR profiling by ATCC. The cells were tested negative for mycoplasma.

**Construction of chimeric SARS-CoV-2s with variant spikes**

All spike mutations from variants were engineered into infectious cDNA clones of an early SARS-CoV-2 isolate, USA-WA1/2020, using a standard PCR-based mutagenesis method\textsuperscript{22}. The full-length cDNAs of viral genomes containing the variant spike mutations were assembled by in vitro ligation. The resulting genome-length cDNAs served as templates for in vitro transcription of full-length viral RNAs. The full-length viral RNA transcripts were electroporated into Vero E6 cells. On day 2 post electroporation (when the electroporated cells developed cytopathic effects due to recombinant virus production and replication), the original viral stocks (P0) were harvested from culture medium. The P0 viruses were amplified on Vero E6 cells for another round to produce working viral stocks (P1). The infectious titers of the P1 viruses were quantified by plaque assay on Vero E6 cells\textsuperscript{24}. The complete spike genes from the P1 viruses were sequenced to ensure no undesired mutations. The P1 viruses were used for neutralization tests.

**Characterization of wild-type and chimeric SARS-CoV-2's with variant spikes**

We quantified the P1 stocks for their genomic RNA content by RT-qPCR and for their infectious titers by plaque assay on Vero E6 cells. RNA copies of SARS-CoV-2 samples were detected by quantitative real-time RT-PCR assays using the Taq SYBR Green One-Step Kit (Bio-Rad) on the LightCycler 480 system (Roche, Indianapolis, IN) following the manufacturer's protocols. The absolute quantification of viral RNA was determined by a standard curve method using an RNA standard (in vitro transcribed 3480 bp containing genomic nucleotide positions 26,044 to 29,883 of SARS-CoV-2 genome)\textsuperscript{25}. Infectious titers of SARS-CoV-2 samples were detected by plaque assay. Approximately 1.2 x 10\textsuperscript{6} Vero-E6 cells were seeded to each well of six-well plates and cultured at 37 °C, 5% CO\textsubscript{2} for 16 h. Virus was serially diluted in DMEM with 2% FBS and 200 µl diluted viruses were transferred onto the monolayers. The viruses were incubated with the cells at 37 °C with 5% CO\textsubscript{2} for 1 h. After the incubation, overlay medium was added to the infected cells per well. The overlay medium contained DMEM with 2% FBS, 1% penicillin/streptomycin, and 1% seaplaque agarose (Lonza, Walkersville, MD). After a 2-day incubation, the plates were stained with neutral red (Sigma-Aldrich, St. Louis, MO) and plaques were counted on a lightbox. The detection limit of the plaque assay was 10 PFU/ml. The ratio of viral RNA to PFU was calculated to indicate the specific infectivity of each virus.

**BNT162b2-vaccinated human sera**

A panel of 20 serum samples were collected from 15 BNT162b2 vaccinees participating in the phase 1 portion of the ongoing phase 1/2/3 clinical trial (ClinicalTrials.gov identifier: NCT04368728)\textsuperscript{5,14}. The participants provided written informed consent to take part in the study. The protocol and informed consent were approved by institutional review boards for each of the investigational centers participating in the study. The study was conducted in compliance with all International Council for Harmonisation Good Clinical Practice guidelines and the ethical principles of the Declaration of Helsinki. The sera were collected 2 or 4 weeks after two doses of 30 µg of BNT162b2 mRNA, spaced 3 weeks apart. As indicated in Supplementary Table 1, 5 of the 20 participants provided sera at both 2 and 4 weeks after the second dose of vaccine. The ages of human subjects are also presented in Supplementary Table 1. The serum donors were White, except for one donor who was Asian. All donors were of non-Hispanic/non-Latino ethnicity.

**Plaque-reduction neutralization test**

A conventional 50% plaque-reduction neutralization test (PRNT\textsubscript{50}) was performed to measure the neutralizing titers of individual serum specimens\textsuperscript{15,16}. The Vero E6 cells (1.2 x 10\textsuperscript{6} per well) were seeded to six-well plates. On the following day, individual sera were twofold serially diluted in culture medium with a starting dilution of 1:40. One hundred PFUs of WT or chimeric SARS-CoV-2 with variant spike were mixed with the serially diluted sera. After incubation at 37 °C for 1 h, the serum/virus mixtures were inoculated on to six-well plates with a monolayer of Vero E6 cells. After another 1 h incubation at 37 °C, 2 ml of 1% seaplaque agarose in DMEM containing 2% FBS and 1% P/S were added to the infected cells. Two days later, the plaques were stained by neutral red and counted on the white light board. The PRNT\textsubscript{50} titer was defined as the minimal serum dilution that suppressed >50% of viral plaques.

**Statistical analysis**

Statistical analyses were performed by Graphpad Prism 9 for all experiments as detailed in legends to individual figures.

**Reporting summary**

Further information on research design is available in the Nature Research Reporting Summary linked to this article.
DATA AVAILABILITY
Source data for generating the main figure are available in the online version of the paper. Any other information is available upon request.

Received: 29 September 2021; Accepted: 15 March 2022; Published online: 08 April 2022

REFERENCES
1. Brown, C. M. et al. Outbreak of SARS-CoV-2 infections, including COVID-19 vaccine breakthrough infections, associated with large public gatherings — Barnstable County, Massachusetts, 2021. Morb. Mortal. Weekly Rep. https://www.cdc.gov/mmwr/volumes/70/wr/mm7031e7032.htm?s_cid:mm7031e7032_wfb&fbclid=IwAR7032W7036ul_A-I_VN_7015XX7034bedb7038CelJNKrWidZ-bJUuWm2MKbs7094xd61PIs (2021).
2. Chen, R. E. et al. Resistance of SARS-CoV-2 variants to neutralization by monoclonal and serum-derived polyclonal antibodies. *Nat. Med.* 27, 717–726 (2021).
3. Hou, Y. J. et al. SARS-CoV-2 Delta variant replication and immune evasion. *Science* 370, 1464–1468 (2020).
4. Liu, Y. et al. The N501Y spike substitution enhances SARS-CoV-2 transmission. *Nature* 602, 294–299 (2022).
5. Plante, J. A. et al. Spike mutation D614G alters SARS-CoV-2 fitness. *Nature* 592, 116–121 (2021).
6. Polack, F. P. et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 Vaccine. *N. Engl. J. Med.* 383, 2603–2615 (2020).
7. Vogel, A. B. et al. BNT162b vaccines protect rhesus macaques from SARS-CoV-2. *Nature* 592, 283–289 (2021).
8. Abu-Raddad, L. J., Cherniatielly, H. & Butt, A. A., National Study Group for, C.V. Effectiveness of the BNT162b2 Covid-19 vaccine against the B.1.1.7 and B.1.351 Variants. *N. Engl. J. Med.* 385, 187–189 (2021).
9. Edara, V. V. et al. Infection and vaccine-induced neutralizing-antibody responses to the SARS-CoV-2 B.1.617 variants. *N. Engl. J. Med.* https://doi.org/10.1056/NEJMoa2107799 (2021).
10. Liu, J. et al. BNT162b2-elicited neutralization of B.1.617 and other SARS-CoV-2 variants. *Nature*, https://doi.org/10.1038/s41586-021-03693-y (2021).
11. Liu, Y. et al. Neutralizing Activity of BNT162b2-Elicited Serum. *N. Engl. J. Med.* 384, 1466–1468 (2021).
12. Liu, Y. et al. BNT162b2-Elicited Neutralization against New SARS-CoV-2 Spike Variants. *N. Engl. J. Med.* https://doi.org/10.1056/NEJMoa2106083 (2021).
13. Planas, D. et al. Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization. *Nature*, https://doi.org/10.1038/s41586-021-03777-9 (2021).
14. Walsh, E. E. et al. Safety and immunogenicity of two RNA-based Covid-19 vaccine candidates. *N. Engl. J. Med.* 383, 2439–2450 (2020).
15. Thomas, S. J. et al. Safety and efficacy of the BNT162b2 mRNA COVID-19 vaccine through 6 Months. *N. Engl J Med.* 385, 1761–1773 (2021).
16. Xie, X. et al. Neutralization of SARS-CoV-2 spike 69/70 deletion, E484K and N501Y variants by BNT162b2 vaccine-elicited sera. *Nat. Med.* 27, 620–621 (2021).
17. Falsey, A. R. et al. SARS-CoV-2 Neutralization with BNT162b2 Vaccine Dose 3. *N. Engl. J. Med.* https://doi.org/10.1056/NEJMoa2113468 (2021).
18. Liu, Y. et al. Delta spike P681R mutation enhances SARS-CoV-2 fitness over Alpha variant. Preprint at BioRxiv, https://doi.org/10.1101/2021.08.12.456173 (2021).
19. Mlcochova, P. et al. SARS-CoV-2 B.1.617.2 Delta variant replication and immune evasion. *Nature* 599, 114–119 (2021).
20. Li, B. et al. Viral infection and transmission in a large, well-traced outbreak caused by the SARS-CoV-2 Delta variant. *Nat. Commun.* 13, 1–9 (2022).
21. Steinhauer, D. A. Role of hemagglutinin cleavage for the pathogenicity of influenza virus. *Virology* 258, 1–20 (1999).
22. Xie, X. et al. An infectious cDNA clone of SARS-CoV-2. *Cell Host Microbe* 27, 841–848 (2020). e843.
23. Xie, X. et al. Engineering SARS-CoV-2 using a reverse genetic system. *Nat. Protoc.* 16, 1761–1784 (2021).
24. Murasato, A. E. et al. A high-throughput neutralizing antibody assay for COVID-19 diagnosis and vaccine evaluation. *Nat. Commun.* 11, 4059 (2020).

ACKNOWLEDGEMENTS
We thank the participants from Pfizer-BioNTech clinical trial C4591001, who donated the post-vaccination sera. We also thank the colleagues at Pfizer and BioNTech who developed and produced the BNT162b2 vaccine candidate. We thank Qi Yang for analysis of variant sequences. The study was supported by Pfizer and BioNTech.

AUTHOR CONTRIBUTIONS
J.L. and Y.L. made equal contributions to the study. Conceptualization, K.U.J., U.S., X.X., K.A.S., A.M., P.R.D., P.-Y.S.; Methodology, J.L., Y.L., H.X., J.Z., S.C.W., K.A.S., H.C., A.M., K.U.J., U.S., X.X., P.R.D., P.-Y.S.; Investigation, J.L., Y.L., H.X., J.Z., S.C.W., K.A.S., H.C., M.C., D.C., K.U.J., U.S., X.X., P.R.D., P.-Y.S.; Data Curation, J.L., Y.L., M.C., D.C., XX., P.-Y.S.; Writing—Original Draft, J.L., Y.L., X.X., P.R.D., P.-Y.S.; Writing—Review & Editing, S.C.W., K.A.S., A.M., K.U.J., U.S., XX., P.R.D., P.-Y.S.; Supervision, K.U.J., U.S., XX., P.R.D., P.-Y.S.; Funding Acquisition, K.U.J., U.S., P.R.D., P.-Y.S.

COMPETING INTERESTS
The authors declare that there are no competing interests. X.X. and P.-Y.S. have filed a patent on the reverse genetic system and reporter of SARS-CoV-2. K.A.S., H.C., M.C., D.C., K.U.J. and P.R.D. are employees of Pfizer and may hold stock options. A.M. and U.S. are employees of BioNTech and may hold stock options. Y.L., H.X., J.Z., XX. and P.-Y.S. received compensation from Pfizer to perform the neutralization assay.

ADDITIONAL INFORMATION
Supplementary information The online version contains supplementary material available at https://doi.org/10.1038/s41541-022-00462-4.

Correspondence and requests for materials should be addressed to Xuping Xie, Philip R. Dormitzer or Pei-Yong Shi.

Reprints and permission information is available at http://www.nature.com/reprints

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2022